Welcome to our dedicated page for XYN news (Ticker: XYN), a resource for investors and traders seeking the latest updates and insights on XYN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XYN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XYN's position in the market.
Xynomic Pharmaceuticals Holdings, Inc. (OTC: XYNO) announced a merger with Xu-Nuo Pharma, Inc., effectively going private as of June 17, 2021. The merger allows Xynomic shareholders to receive US$4.49 per share as cash consideration, while their shares will be delisted from the OTC Pink Marketplace. Since Xu-Nuo holds approximately 98% of Xynomic's outstanding shares, shareholder voting was not required, but dissenters' rights are available under Delaware law. Post-merger, Xu-Nuo will continue Xynomic's business operations.
